Efficacy and safety of anlotinib in bevacizumab-pretreated patients with non-squamous non-small cell lung cancer (AN-BELIEF study): a multicenter retrospective study.
6 affiliations
- 1Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
- 2Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- 3Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- 4Department of Medical Oncology, Sichuan Provincial People's Hospital, Chengdu, China.
- 5Department of Medical Oncology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- 6Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Abstract
Given the growing population of patients with disease progression following bevacizumab-based regimens, effective post-bevacizumab antiangiogenic options remain an unmet need. We aimed to evaluate the efficacy and safety of anlotinib in this specific population of non-squamous non-small cell lung cancer (NSCLC). This multicenter retrospective cohort study enrolled patients from six hospitals between January 2018 and May 2024. Eligible patients had non-squamous NSCLC and received bevacizumab-containing treatment, or received anlotinib monotherapy without prior bevacizumab exposure. Key exclusions included anlotinib initiation before bevacizumab treatment, the use of other antiangiogenic tyrosine kinase inhibitors after bevacizumab, or insufficient radiologic evaluation. Patients were grouped by prior bevacizumab exposure and subsequent treatment. Tumor response was assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, with progression-free survival (PFS) as the primary endpoint; secondary endpoints included the objective response rate (ORR) and disease control rate (DCR), and adverse events (AEs), with AEs assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Of 1,256 screened patients, 746 were included in the original cohort: 174 bevacizumab-naïve (bevacizumab-naïve) patients who received anlotinib monotherapy, and 572 bevacizumab-pretreated patients who were further divided into anlotinib monotherapy (n=108), anlotinib-based combination therapy (n=345), or other therapies (n=119). In the cohort, bevacizumab-naïve patients attained significantly longer PFS than bevacizumab-pretreated patients receiving anlotinib monotherapy [8.23 vs. 5.90 months; hazard ratio (HR), 1.41; P=0.003]. However, after propensity score matching (PSM) to balance covariates, this difference was no longer significant (6.43 vs. 7.60 months; HR 1.14, P=0.33). Among bevacizumab-pretreated patients, PFS did not differ significantly among the three treatment groups before matching (P=0.42); after PSM, anlotinib monotherapy and other therapies showed similar PFS (5.90 vs. 5.23 months; HR 0.96, P=0.77), whereas anlotinib combination therapy group was associated with a significantly longer PFS compared with other therapies (6.50 vs. 5.23 months; HR 0.82, P=0.048). Anlotinib showed clinical activity in this selected retrospective cohort of bevacizumab-pretreated patients with non-squamous NSCLC. Anlotinib-based combination therapy was associated with longer PFS than other subsequent therapies after adjustment for baseline differences; however, these findings require confirmation in larger prospective studies.
Related
- Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study
- Efficacy and safety of sintilimab plus bevacizumab with or without transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score-matched retrospective cohort study
- Atezolizumab plus Bevacizumab with or without Transarterial Chemoembolization as First-Line Treatment for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma: A Nationwide Multicenter Retrospective Study.
- A Multicenter Retrospective Study on the Safety and Efficacy of the Surpass Evolve Flow Diverter System for the Treatment of Intracranial Aneurysms
- Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis
BibTeX
@article{wang2026efficacy,
title = {{Efficacy and safety of anlotinib in bevacizumab-pretreated patients with non-squamous non-small cell lung cancer (AN-BELIEF study): a multicenter retrospective study.}},
author = {Jiale Wang and Xinxin Zhi and Jinzhang Chen and Bingzhong Zhang and Haitao Lan and Feng Jiao and Yiwei Liu and Fengying Wu and Jia Yu and Aiwu Li and Cheng Ji and Qiyu Fang and Shengxiang Ren},
journal = {Translational lung cancer research},
year = {2026},
month = oct,
doi = {10.21037/tlcr-2026-0579},
url = {https://europepmc.org/article/MED/42999610},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Efficacy and safety of anlotinib in bevacizumab-pretreated patients with non-squamous non-small cell lung cancer (AN-BELIEF study): a multicenter retrospective study.
AU - Jiale Wang
AU - Xinxin Zhi
AU - Jinzhang Chen
AU - Bingzhong Zhang
AU - Haitao Lan
AU - Feng Jiao
AU - Yiwei Liu
AU - Fengying Wu
AU - Jia Yu
AU - Aiwu Li
AU - Cheng Ji
AU - Qiyu Fang
AU - Shengxiang Ren
PY - 2026
DA - 2026/10/10
JO - Translational lung cancer research
DO - 10.21037/tlcr-2026-0579
UR - https://europepmc.org/article/MED/42999610
AB - Given the growing population of patients with disease progression following bevacizumab-based regimens, effective post-bevacizumab antiangiogenic options remain an unmet need. We aimed to evaluate the efficacy and safety of anlotinib in this specific population of non-squamous non-small cell lung cancer (NSCLC). This multicenter retrospective cohort study enrolled patients from six hospitals between January 2018 and May 2024. Eligible patients had non-squamous NSCLC and received bevacizumab-containing treatment, or received anlotinib monotherapy without prior bevacizumab exposure. Key exclusions included anlotinib initiation before bevacizumab treatment, the use of other antiangiogenic tyrosine kinase inhibitors after bevacizumab, or insufficient radiologic evaluation. Patients were grouped by prior bevacizumab exposure and subsequent treatment. Tumor response was assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, with progression-free survival (PFS) as the primary endpoint; secondary endpoints included the objective response rate (ORR) and disease control rate (DCR), and adverse events (AEs), with AEs assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Of 1,256 screened patients, 746 were included in the original cohort: 174 bevacizumab-naïve (bevacizumab-naïve) patients who received anlotinib monotherapy, and 572 bevacizumab-pretreated patients who were further divided into anlotinib monotherapy (n=108), anlotinib-based combination therapy (n=345), or other therapies (n=119). In the cohort, bevacizumab-naïve patients attained significantly longer PFS than bevacizumab-pretreated patients receiving anlotinib monotherapy [8.23 vs. 5.90 months; hazard ratio (HR), 1.41; P=0.003]. However, after propensity score matching (PSM) to balance covariates, this difference was no longer significant (6.43 vs. 7.60 months; HR 1.14, P=0.33). Among bevacizumab-pretreated patients, PFS did not differ significantly among the three treatment groups before matching (P=0.42); after PSM, anlotinib monotherapy and other therapies showed similar PFS (5.90 vs. 5.23 months; HR 0.96, P=0.77), whereas anlotinib combination therapy group was associated with a significantly longer PFS compared with other therapies (6.50 vs. 5.23 months; HR 0.82, P=0.048). Anlotinib showed clinical activity in this selected retrospective cohort of bevacizumab-pretreated patients with non-squamous NSCLC. Anlotinib-based combination therapy was associated with longer PFS than other subsequent therapies after adjustment for baseline differences; however, these findings require confirmation in larger prospective studies.
SN - 2218-6751
SN - 2226-4477
ER -